Researchers should be encouraged to develop such carrier systems by the fact that, HLA-I APM-low phenotypes are involved not only in resistance to ICB but also other types of immunotherapy and can be detected also in other tumor entities besides melanoma. This evidence concerns the gene ANPEP and melanoma.